| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX)
ACRX Technical Analysis
4
| As on 9th Jun 2023 ACRX SHARE Price closed @ 1.24 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.49 & Strong Buy for SHORT-TERM with Stoploss of 0.47 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ACRXSHARE Price
| Open | 1.20 | Change | Price | % |
| High | 1.25 | 1 Day | 0.13 | 11.71 |
| Low | 1.12 | 1 Week | 0.13 | 11.71 |
| Close | 1.24 | 1 Month | 0.56 | 82.35 |
| Volume | 315462 | 1 Year | 0.69 | 125.45 |
| 52 Week High 3.69 | 52 Week Low 0.18 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ACRX Daily Charts |
ACRX Intraday Charts |
Whats New @ Bazaartrend |
ACRX Free Analysis |
|
|
ACRX Important Levels Intraday
| RESISTANCE | 1.49 |
| RESISTANCE | 1.41 |
| RESISTANCE | 1.36 |
| RESISTANCE | 1.31 |
| SUPPORT | 1.17 |
| SUPPORT | 1.12 |
| SUPPORT | 1.07 |
| SUPPORT | 0.99 |
ACRX Forecast April 2024
| 4th UP Forecast | 1.68 |
| 3rd UP Forecast | 1.54 |
| 2nd UP Forecast | 1.45 |
| 1st UP Forecast | 1.37 |
| 1st DOWN Forecast | 1.11 |
| 2nd DOWN Forecast | 1.03 |
| 3rd DOWN Forecast | 0.94 |
| 4th DOWN Forecast | 0.8 |
ACRX Weekly Forecast
| 4th UP Forecast | 1.49 |
| 3rd UP Forecast | 1.41 |
| 2nd UP Forecast | 1.36 |
| 1st UP Forecast | 1.31 |
| 1st DOWN Forecast | 1.17 |
| 2nd DOWN Forecast | 1.12 |
| 3rd DOWN Forecast | 1.07 |
| 4th DOWN Forecast | 0.99 |
ACRX Forecast2024
| 4th UP Forecast | 9.2 |
| 3rd UP Forecast | 6.65 |
| 2nd UP Forecast | 5.07 |
| 1st UP Forecast | 3.49 |
| 1st DOWN Forecast | -1.01 |
| 2nd DOWN Forecast | -2.59 |
| 3rd DOWN Forecast | -4.17 |
| 4th DOWN Forecast | -6.72 |
AcelRx Pharmaceuticals Inc ( NASDAQ USA Symbol : ACRX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ACRX Business Profile
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is based in Hayward, California. Address: 25821 Industrial Boulevard, Hayward, CA, United States, 94545
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service